Enveda raises $311 million at a $2 billion valuation, natural intelligence moves plant-derived drugs and weight-loss therapies to human trials

Biotech company Enveda, which leverages artificial intelligence to discover new drugs derived from the natural world, raised $311 million in a Series E financing round, bringing its market valuation to $2 billion. The round was led by Catalio Capital Management, with participation from Iconiq and other investors, doubling the company's valuation compared with twelve months ago.

The company's scientific bet is extracting effective medicines from plants and natural microbes instead of chemically synthesizing them from scratch in the lab.The company was founded in 2019 by Vishva Kulkarni, one of the early employees at Recursion Pharmaceuticals, to accelerate discovery of new therapeutic compounds by combining AI models with advanced biotechnologies. The vision rests on the idea that nature has, over millions of years, evolved highly complex molecular structures that algorithmic systems can decode and pinpoint their biological targets with precision, shortening the long periods of random research and traditional chemical experimentation.

Moving drug candidates into human clinical trials represents the decisive test of AI's viability in healthcare.Despite the growing investment momentum in biotech, AI has yet to produce any drug that receives final official approval from the U.S. Food and Drug Administration (FDA). However, Enveda is among the leading wave of start-ups that have moved algorithm-discovered compounds from the lab into patients. The company is currently conducting clinical trials on several drugs, including a compound targeting severe skin diseases and another designed to counter weight regain and help stabilize weight after discontinuing the popular obesity treatments known as GLP-1 drugs.

Targeting weight stabilization after stopping GLP-1 drugs is a precise intervention in one of the biggest challenges facing obesity and diabetes treatments worldwide, as patients typically regain lost weight once the therapeutic protocol ends. Pursuing compounds derived from plants and microbes offers a therapeutic alternative with biological characteristics distinct from artificially manufactured formulations, which explains investors' interest in doubling the company's valuation to $2 billion to fund costly clinical stages.

This shift carries direct strategic and operational implications for healthcare systems, research centers, and investment funds in the Gulf, Egypt, and the Levant. With the sharp regional rise in demand for GLP-1 drugs and the associated financial burdens on public and private health insurance budgets, the emergence of complementary compounds that maintain weight stability opens avenues to reduce long-term care costs. On the other hand, the progress of clinical trials for algorithm-derived drugs compels regional regulatory and health authorities to update auditing and approval pathways to assess the safety and efficacy of natural molecules discovered through intelligent models. The model also motivates regional universities and national laboratories to employ machine-learning tools to explore local plant and environmental diversity in deserts and arid habitats, converting latent biological knowledge into promising pharmaceutical and industrial assets.

The true measure of AI's value in drug development is no longer the ability to screen billions of molecules on computers, but the success of those compounds in navigating complex clinical stages and demonstrating safety in patients. The real challenge for Enveda and other biotech firms remains turning this massive funding into an approved therapy that reaches pharmacies, ending the lingering question of when AI will deliver its first globally licensed drug.